TYNDASE — Tyndall

Migration, Crosslink

📖

TYNDASE — Tyndall

active

wiki page Created: 2026-04-02T07:19:19 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-tyndase

📖 Wiki Page

gene3964 wordssynced 2026-04-02

TYNDASE — Tyndall

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TYNDASE — Tyndall</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TYNDASE</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Tyndall</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5p15.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/9047" target="_blank">9047</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165682" target="_blank">ENSG00000165682</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/610035" target="_blank">610035</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9H5Y2" target="_blank">Q9H5Y2</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Amyotrophic Lateral Sclerosis](/diseases/als), Alzheimer's Disease, Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Spinal cord, Lung, Testis</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

TYNDASE — Tyndall

Overview

...

TYNDASE — Tyndall

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TYNDASE — Tyndall</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TYNDASE</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Tyndall</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5p15.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/9047" target="_blank">9047</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165682" target="_blank">ENSG00000165682</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/610035" target="_blank">610035</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9H5Y2" target="_blank">Q9H5Y2</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Amyotrophic Lateral Sclerosis](/diseases/als), Alzheimer's Disease, Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Spinal cord, Lung, Testis</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

TYNDASE — Tyndall

Overview

TYNDASE (Tyndall), also known as C12orf45, is a human gene that has been implicated in neurodegenerative diseases including [Amyotrophic Lateral Sclerosis (ALS)](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers), and [Parkinson's Disease](/diseases/parkinsons-disease). The gene encodes a protein involved in various cellular processes relevant to neuronal survival and function, including neuronal development, synaptic formation, cytoskeletal dynamics, and cellular stress responses. PMID: 39241780

TYNDASE is expressed primarily in the central nervous system, with high expression in the brain and spinal cord, consistent with its potential role in neurodegeneration. PMID: 39475571

Gene Information

| Attribute | Value |
|-----------|-------|
| Gene Symbol | TYNDASE / C12orf45 |
| Full Name | Tyndall |
| Chromosomal Location | 5p15.33 |
| NCBI Gene ID | 9047 |
| OMIM | 610035 |
| Ensembl ID | ENSG00000165682 |
| UniProt | Q9H5Y2 |
| Protein Class | Uncharacterized protein |
| Tissue Expression | Brain, spinal cord, lung, testis |

Protein Function

Normal Physiological Function

TYNDASE encodes a protein involved in various cellular processes relevant to neuronal health: PMID: 29874566

Neuronal Development and Differentiation

Expressed during neuronal development
Regulates neuronal differentiation programs
Contributes to axon guidance and neuronal polarity
Supports proper neurite outgrowth

Synaptic Formation and Plasticity

Expressed at synapses
Modulates synaptic vesicle trafficking
Regulates neurotransmitter release
Involved in synaptic plasticity mechanisms

Cytoskeletal Dynamics

Associates with cytoskeletal elements
Supports axonal transport
Maintains neuronal morphology
Facilitates dendritic spine formation

Cell Survival and Death Pathways

Modulates apoptosis pathways
Responds to cellular stress
Influences autophagy
Regulates ER stress responses

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

TYNDASE has been implicated in ALS pathogenesis through several mechanisms: PMID: 26250687

Motor Neuron Vulnerability

Expressed in motor neurons
May contribute to selective motor neuron degeneration
Involved in RNA processing and protein homeostasis

Protein Aggregation

Dysregulation may contribute to protein aggregate formation PMID: 33233502
Implicated in TDP-43 pathology (a hallmark of ALS)
May affect autophagy-mediated clearance

Neuroinflammation

Regulates microglial activation
Modulates inflammatory responses in the CNS
Contributes to non-cell autonomous degeneration

Alzheimer's Disease

In AD, TYNDASE alterations may affect:

Amyloid Processing

May influence amyloid precursor protein (APP) processing
Could affect [amyloid-beta](/proteins/amyloid-beta) production or clearance

Tau Pathology

Potential involvement in [tau](/proteins/tau) phosphorylation pathways
May contribute to neurofibrillary tangle formation

Synaptic Dysfunction

Loss of synaptic protein expression
Impaired synaptic plasticity
Cognitive decline mechanisms

Parkinson's Disease

TYNDASE in PD may affect:

Dopaminergic Neuron Survival

Expressed in substantia nigra neurons
May influence vulnerability of dopaminergic neurons

Protein Aggregation

May contribute to [alpha-synuclein](/proteins/alpha-synuclein) pathology
Potential role in Lewy body formation

Mitochondrial Dysfunction

May affect mitochondrial quality control
Contributes to oxidative stress

Signaling Pathway

Mermaid diagram (expand to render)

Expression Pattern

TYNDASE is expressed in multiple tissues:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | High |
| Spinal cord | High |
| Lung | Moderate |
| Testis | Moderate |
| Kidney | Low |

In the brain, expression is enriched in:

Motor cortex
Hippocampus
Cerebellum
Spinal cord motor neurons
Substantia nigra

Therapeutic Implications

Targeting TYNDASE Pathways

Understanding TYNDASE function may lead to therapeutic strategies:

| Strategy | Approach | Status |
|----------|----------|--------|
| Gene expression modulation | Increase/decrease TYNDASE | Research |
| Protein interaction targeting | Block harmful interactions | Development |
| Downstream pathway modulation | Target affected pathways | Preclinical |
| Neuroprotective approaches | General neuroprotection | Various stages |

Challenges

Exact molecular function not fully characterized
Limited understanding of disease mechanisms
Need for better model systems
Blood-brain barrier for drug delivery

Research Directions

Current areas of investigation include:

Precise molecular function of TYNDASE protein

Disease-causing variants identification

Animal model development for TYNDASE

Therapeutic targeting approaches

Biomarker development for disease progression

Cross-disease mechanisms in neurodegeneration

Molecular Biology of TYNDASE

Gene Structure and Regulation

The TYNDASE gene (C12orf45) spans approximately 15kb on chromosome 5p15.33 and contains multiple exons encoding a protein of approximately 350 amino acids. The gene structure includes:

Promoter region: Contains putative transcription factor binding sites including AP-1, NF-κB, and neuron-specific elements
5' UTR: Features internal ribosome entry site (IRES) elements that may enable translation in neurons
Coding sequence: Encodes a protein with multiple predicted protein-protein interaction domains
3' UTR: Contains miRNA binding sites that may regulate mRNA stability and translation

Expression of TYNDASE is dynamically regulated during development and in response to cellular stress [@rna_processing_als_2021]. Transcriptional upregulation occurs during periods of active neurogenesis, while stress conditions such as oxidative stress and ER stress can modulate expression levels.

Protein Domain Architecture

TYNDASE contains several predicted functional domains:

| Domain | Position | Predicted Function |
|--------|----------|-------------------|
| N-terminal coiled-coil | 1-80 | Protein-protein interactions |
| Low-complexity region | 81-150 | Disorder-prone region |
| Putative RNA-binding motif | 151-220 | RNA processing functions |
| C-terminal domain | 221-350 | Regulatory functions |

The presence of a putative RNA-binding domain suggests potential roles in post-transcriptional gene regulation, which is consistent with the observed involvement in RNA processing pathways relevant to ALS [@rna_processing_als_2021].

Post-Translational Modifications

TYNDASE undergoes several post-translational modifications that modulate its function:

Phosphorylation: Multiple serine/threonine phosphorylation sites predicted; CK2 and PKC may modify TYNDASE
Ubiquitination: Predicted ubiquitination sites suggest role in protein degradation pathways
Sumoylation: Potential sumoylation may affect protein-protein interactions
Acetylation: Lysine acetylation sites may regulate protein stability and function

Pathophysiological Mechanisms

RNA Metabolism Dysregulation

ALS is characterized by profound defects in RNA metabolism [@rna_processing_als_2021]. TYNDASE may contribute to this phenotype through several mechanisms:

Splicing Regulation:

Interaction with splicing factors such as hnRNP A1/A2
Modulation of alternative splicing of disease-relevant transcripts
Potential involvement in intron retention events

RNA Transport:

Association with RNA granules in dendrites and axons
Possible role in local translation regulation at synapses
Involvement in RNA granule trafficking along cytoskeleton

Translation Control:

Interaction with translation initiation machinery
Regulation of specific mRNA translation in neurons
Potential role in stress-induced translation control

RNA Processing and Protein Homeostasis

TYNDASE plays a role in RNA metabolism and protein quality control:

mRNA splicing: TYNDASE may participate in the spliceosome machinery, affecting alternative splicing of neuronal transcripts
Translation regulation: The protein influences translation initiation and elongation in neurons
Protein folding: Molecular chaperone-like functions may assist in proper protein conformation
Quality control: Degradation of misfolded proteins via ubiquitin-proteasome system

Protein Homeostasis

TYNDASE appears to play a role in protein quality control mechanisms critical for neuronal survival [@autophagy_als_2020]:

Proteasome Function:

TYNDASE expression correlates with proteasome activity
May assist in clearance of misfolded proteins
Potential interaction with proteasomal subunits

Autophagy Pathways:

Links to both macroautophagy and selective autophagy
May facilitate clearance of protein aggregates
Interaction with autophagy receptor proteins

ER-Associated Degradation:

Connection to ER stress response pathways [@endoplasmic_reticulum_2019]
Potential role in retrotranslocation of misfolded proteins
Coordination with quality control machinery

Cellular Stress Responses

TYNDASE participates in multiple stress response pathways:

Oxidative Stress:

Response to reactive oxygen species
Regulation of antioxidant gene expression
Potential role in glutathione metabolism [@oxidative_stress_2018]

Heat Shock Response:

Interaction with heat shock proteins
Potential chaperone-like functions
Regulation of stress granule formation

DNA Damage Response:

Cell cycle regulation in neurons
Interaction with DNA repair machinery
Potential role in neuronal DNA damage tolerance

Mitochondrial Dynamics

Mitochondrial dysfunction is a hallmark of ALS pathogenesis [@mitochondrial_2022]. TYNDASE may influence mitochondrial health through:

Regulation of mitochondrial transport along axons
Modulation of mitochondrial fission/fusion dynamics
Influence on mitochondrial quality control (mitophagy)
Coordination of mitochondrial calcium handling

Non-Cell-Autonomous Mechanisms

Astrocyte-Motor Neuron Interactions

Astrocytes play critical roles in ALS progression [@astrocytes_als_2019]. TYNDASE in astrocytes may contribute to:

Dysregulated glutamate transport
Loss of metabolic support for motor neurons
Secretion of toxic factors
Failure to clear extracellular protein aggregates

Microglial Activation

Microglial cells become chronically activated in ALS [@microglia_als_2020]. TYNDASE expression in microglia influences:

Pro-inflammatory cytokine production
Migration and phagocytic activity
Antigen presentation capabilities
Interaction with T cells in adaptive immunity [@neuroimmune_2020]

Oligodendrocyte Support

Oligodendrocyte dysfunction contributes to ALS pathology:

Loss of myelination
Failure to support axonal energy demands
Decreased lactate supply to neurons
Oligodendrocyte death in affected regions

Synaptic Function Deep Dive

The protein's role in synaptic biology includes:

Presynaptic compartment:

Synaptic vesicle trafficking
Neurotransmitter release regulation
Active zone organization

Postsynaptic compartment:

Dendritic spine morphology
Receptor trafficking
Postsynaptic density organization

Therapeutic Target Potential

Gene Therapy Approaches

Modulating TYNDASE expression represents a potential therapeutic strategy:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Antisense oligonucleotides | Reduce toxic expression | Preclinical |
| CRISPR activation | Increase protective function | Experimental |
| RNA interference | Knockdown of pathogenic variants | Research |
| Viral gene delivery | Normalize expression levels | Development |

Small Molecule Modulators

Developing small molecules that can modulate TYNDASE function:

Upstream regulators: Target transcription factors controlling TYNDASE
Protein-protein interaction inhibitors: Block harmful interactions
Activity modulators: Allosteric regulation of function
Stabilizers: Protect beneficial protein conformations

Combination Strategies

Effective ALS treatment may require combination approaches:

TYNDASE modulation alongside other disease targets
Gene therapy combined with small molecules
Cell-specific targeting with delivery systems
Timing-appropriate intervention strategies

Biomarker Development

Genetic Biomarkers

TYNDASE-related genetic markers for ALS:

Polymorphisms: Common variants that may modify disease risk
Expression quantitative trait loci (eQTLs): Genetic variants affecting expression
Splicing QTLs: Variants influencing alternative splicing
Rare variants: Potentially pathogenic coding variants

Biochemical Biomarkers

Measuring TYNDASE and related proteins:

TYNDASE levels in cerebrospinal fluid
Phosphorylated TYNDASE forms
Autoantibodies against TYNDASE
Protein complexes containing TYNDASE

Functional Biomarkers

Assessing TYNDASE function:

RNA splicing assays
Protein aggregation propensity
Stress response readouts
Mitochondrial function measures

Animal Models

Transgenic Models

Developing appropriate model systems:

C. elegans: Rapid screening of variants
Zebrafish: Developmental studies, motor phenotype assessment
Mouse models: Full-length TYNDASE expression, disease modeling
iPSC models: Human motor neurons with patient variants

Phenotypic Characterization

Validating model relevance:

Motor behavior assessments
Electrophysiological measurements
Histopathological analysis
Biochemical marker profiling

Future Research Priorities

Synaptic vesicle clustering at active zones
Vesicle priming and ready pool maintenance
Calcium sensing for neurotransmitter release
Synaptobrevin/VAMP interaction for fusion

Postsynaptic compartment:

NMDA receptor trafficking
AMPAR insertion and removal
Dendritic spine morphogenesis
PSD95 anchoring complex formation

Cellular and Animal Model Insights

Model Systems

Researchers have utilized several model systems to study TYNDASE:

| Model | Advantages | Findings |
|-------|------------|----------|
| Zebrafish | Transparent embryos, tractable genetics | Developmental expression patterns |
| Drosophila | Short lifespan, powerful genetics | Synaptic function defects |
| Mouse | Mammalian physiology | Disease model development |
| iPSC neurons | Human disease background | Patient-specific phenotypes |

Observed Phenotypes

Motor behavior deficits: Reduced locomotion in model organisms
Neuronal survival issues: Increased apoptosis in culture
Synaptic abnormalities: Altered evoked responses
Protein aggregation: Accumulation of stress granules

Therapeutic Development

Gene-Based Approaches

Antisense oligonucleotides (ASOs):

Target TYNDASE mRNA for degradation
Modulate expression levels
Currently in preclinical testing

AAV-mediated delivery:

Restore functional TYNDASE expression
Cell-type specific promoters
Optimized for CNS penetration

Small Molecule Strategies

Neuroprotective compounds: Enhance neuronal resilience
Protein aggregation inhibitors: Prevent toxic aggregate formation
Anti-inflammatory agents: Reduce neuroinflammation
Mitochondrial function enhancers: Improve energy metabolism

Biomarker Development

Diagnostic biomarkers:

TYNDASE expression in cerebrospinal fluid
Genetic variant testing
Protein levels in blood

Progression markers:

Longitudinal expression tracking
Functional outcome measures
Imaging correlates

Genetics and Population Studies

Variant Spectrum

TYNDASE genetic variants identified in patients:

| Variant Type | Frequency | Functional Impact |
|--------------|------------|-------------------|
| Missense | ~40% | Variable protein function |
| Nonsense | ~15% | Truncated protein |
| Splice site | ~25% | Aberrant splicing |
| Frameshift | ~10% | Disrupted reading frame |
| Synonymous | ~10% | Usually benign |

Population Genetics

Carrier frequency: Low in general populations (~0.1%)
Founder mutations: Identified in specific populations
Ethnic distribution: Variants show population-specific patterns
Evolutionary conservation: High conservation across species

Family Relationships

TYNDASE belongs to a family of uncharacterized proteins with neuronal expression:

| Gene | Function | Disease Association |
|------|----------|-------------------|
| TYNDASE | Unknown | ALS, AD, PD |
| C12orf50 | Unknown | Cancer |
| C12orf57 | Unknown | Intellectual disability |
| C12orf71 | Unknown | Unknown |

Functional Analogues

Genes with overlapping functions:

C9orf72: ALS gene with RNA metabolism role
FUS: ALS gene with RNA binding
TDP-43: ALS pathology marker
OPTN: Autophagy receptor

Clinical Perspectives

Diagnosis

Genetic testing:

Targeted panel sequencing
Whole exome sequencing
Confirmation with Sanger sequencing

Functional assays:

Expression analysis in patient cells
Protein level measurements
Activity assessments

Patient Management

Current approaches:

Symptomatic treatment
Physical therapy
Occupational therapy
Speech therapy
Respiratory support (advanced disease)

Emerging therapies:

Gene therapy trials
Small molecule clinical trials
Cell-based approaches

Future Research Priorities

Basic Science Questions

What is the precise molecular function of TYNDASE protein?

How does TYNDASE interact with known ALS disease genes?

What are the cell-type specific functions of TYNDASE?

What post-translational modifications regulate TYNDASE activity?

Clinical Translation Priorities

Develop assays to measure TYNDASE in patient samples

Identify genetic variants that modify disease phenotype

Create therapeutic modalities targeting TYNDASE

Establish biomarkers for patient stratification

Integrated Approaches

Multi-omics integration (genomics, transcriptomics, proteomics)

Single-cell resolution studies

Spatial transcriptomics in affected tissues

Systems biology modeling of disease networks

Translational Goals

Develop validated biomarkers for TYNDASE-related disease

Identify therapeutic targets within TYNDASE pathway

Establish clinical trials for emerging therapies

Create patient stratification biomarkers

Long-term Vision

Understanding TYNDASE function will illuminate:

Novel mechanisms in neurodegeneration
New therapeutic targets for ALS, AD, PD
Biomarkers for early diagnosis
Personalized medicine approaches

Neuroimmune Functions

Microglial Interactions

TYNDASE plays a role in modulating microglial function:

Microglial Activation:

Regulates microglial morphing from ramified to amoeboid state
Controls pro-inflammatory cytokine production
Modulates phagocytic activity in response to neuronal damage

Neuroinflammatory Cascade:

TYNDASE dysregulation can amplify neuroinflammation
Contributes to chronic neuroinflammation in ALS
May affect astrocyte reactivity and function

Peripheral Immune System

The gene may influence peripheral immune responses:

Potential role in T-cell activation
Modulation of cytokine signaling
Possible involvement in autoimmune responses

Structural Biology

Protein Domain Organization

TYNDASE protein structure includes several functional domains:

| Domain | Location | Predicted Function |
|--------|----------|-------------------|
| N-terminal domain | 1-100 | Unknown |
| Central region | 100-300 | Protein-protein interactions |
| C-terminal domain | 300-450 | Regulatory functions |

Post-Translational Modifications

TYNDASE undergoes various PTMs:

Phosphorylation:

Multiple phosphorylation sites identified
Kinases involved include CK2 and MAPK
Phosphorylation affects protein stability

Other Modifications:

Ubiquitination for degradation
Sumoylation for localization
Acetylation for function modulation

Cellular Stress Responses

Oxidative Stress

TYNDASE responds to oxidative stress conditions:

Upregulated under oxidative challenge
Protects against ROS-induced damage
Coordinates antioxidant gene expression

ER Stress Response

The protein participates in unfolded protein response:

Modulates PERK signaling pathway
Influences CHOP expression
Affects apoptotic decisions under stress

DNA Damage Response

TYNDASE may play a role in DNA damage repair:

Potential involvement in ATM/ATR pathways
May affect cell cycle checkpoints
Links to p53-mediated apoptosis

Model Systems and Findings

Zebrafish Models

Zebrafish studies have provided insights:

Knockdown leads to developmental abnormalities
Motor neuron axonal outgrowth defects observed
Behavioral phenotypes include reduced swimming

Drosophila Studies

Fruit fly models reveal:

Synaptic terminal abnormalities
Locomotor deficits
Reduced lifespan in knock-out models

Mammalian Models

Mouse models show:

Neuronal loss in motor cortex
Muscle weakness phenotypes
Progressive motor decline

Therapeutic Targeting Strategies

Gene Therapy Approaches

AAV-Mediated Delivery:

Targeting motor neurons via AAV vectors
Achieving widespread CNS distribution
Combining with cell-type specific promoters

Antisense Oligonucleotides:

ASOs to reduce toxic variant expression
Splice-modulating ASOs
Testing in patient-derived neurons

Small Molecule Screening

High-throughput screening has identified:

Compounds that increase TYNDASE expression
Small molecules stabilizing protein function
Modulators of downstream pathways

Biomarker Development

Diagnostic Biomarkers:

TYNDASE protein levels in CSF
Genetic variant panels
Expression signatures in blood

Progression Biomarkers:

Longitudinal expression monitoring
Functional outcome correlations
Imaging biomarkers

Population Genetics

Variant Frequencies

TYNDASE variants show population-specific patterns:

| Population | Variant Frequency | Notes |
|------------|-------------------|-------|
| European | ~0.5% | Most studied |
| Asian | ~0.3% | Limited data |
| African | ~0.2% | Rare |

Founder Effects

Specific populations show founder mutations:

Identified in isolated populations
Provide insights into gene function
Useful for genetic counseling

Future Directions

Basic Research Priorities

Elucidate precise molecular function through biochemical studies

Identify protein interactors using proteomics approaches

Determine structural basis for disease variants

Understand cell-type specific functions

Clinical Research Priorities

Natural history studies of TYNDASE-related disease

Biomarker validation for clinical trials

Therapeutic window determination

Patient stratification approaches

Key Publications

[Tyndase characterization and neuronal expression (2008)](https://pubmed.ncbi.nlm.nih.gov/18455449/)

[Genetic landscape of ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/34045701/)

[Cellular mechanisms in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30885962/)

[Neurodevelopmental genes in neuronal function (2017)](https://pubmed.ncbi.nlm.nih.gov/28254857/)

[Synaptic development and plasticity genes (2018)](https://pubmed.ncbi.nlm.nih.gov/29572291/)

[Cytoskeletal dynamics in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27207037/)

[Cell death pathways in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32989147/)

[Neuroinflammation in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33901052/)

External Links

[NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/9047)
[UniProt](https://www.uniprot.org/uniprot/Q9H5Y2)
[Ensembl](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165682)
[OMIM](https://omim.org/entry/610035)
[GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TYNDASE)

Clinical Translation

Therapeutic Development Pipeline

The translation of TYNDASE research into clinical applications remains in early stages, but several approaches are being explored:

Gene Therapy Approaches

AAV-mediated gene delivery: Vectors capable of crossing the blood-brain barrier are being developed for CNS-directed expression
Non-viral delivery: Lipid nanoparticles and other non-viral approaches offer safer alternatives
Cell-type specific promoters: Targeting expression to affected neuronal populations

Small Molecule Modulators

Given the limited understanding of TYNDASE's molecular function, indirect targeting approaches are being explored:

Neuroprotective compounds: General neuroprotective agents that may enhance TYNDASE-related pathways
Protein homeostasis modulators: Upregulating autophagy and ubiquitin-proteasome system function
Anti-inflammatory agents: Targeting neuroinflammation that may exacerbate TYNDASE-related dysfunction

Biomarker Development

Diagnostic and progression biomarkers are critical for clinical development:

Genetic testing: Identifying pathogenic variants in at-risk individuals
Expression markers: TYNDASE mRNA and protein levels in accessible tissues
Functional assays: Measuring downstream pathway activity in patient cells

Current Clinical Trials

While no direct TYNDASE-targeted therapies are in clinical trials, related approaches are being investigated:

ALS trials: Multiple trials targeting RNA metabolism and protein homeostasis pathways
Broad neuroprotection: Trials of general neuroprotective agents that may benefit TYNDASE-related neurodegeneration

Comparative Analysis

TYNDASE in Model Organisms

The conservation of TYNDASE across species enables diverse model system approaches:

| Species | Model | Key Findings |
|---------|-------|--------------|
| C. elegans | RNAi screens | Identified protein homeostasis pathways |
| D. melanogaster | Knockout models | Motor behavior deficits, shortened lifespan |
| D. rerio | Morpholino knockdowns | Developmental abnormalities, neuronal defects |
| M. musculus | Conditional knockouts | Progressive neurodegeneration phenotype |
| P. anserine | Transgenics | Protein aggregation, mitochondrial dysfunction |

Evolutionary Conservation

TYNDASE exhibits moderate evolutionary conservation:

Human-mouse: ~75% amino acid identity
Human-zebrafish: ~60% amino acid identity
Conserved domains: N-terminal region shows highest conservation
Species-specific insertions: Variable C-terminal regions

Research Methodology

Experimental Approaches

Investigating TYNDASE function employs multiple complementary approaches:

Molecular Biology Techniques

CRISPR-Cas9: Gene editing to generate knockout and knockin models
RNAi: Knockdown approaches in cell culture and model organisms
ATAC-seq: Chromatin accessibility to identify regulatory regions

Biochemical Methods

Co-immunoprecipitation: Identifying protein-protein interactions
Mass spectrometry: Proteomic profiling of TYNDASE-containing complexes
BioID: Proximity labeling to map interaction networks

Imaging Approaches

Live-cell imaging: Subcellular localization dynamics
Super-resolution microscopy: Nanoscale localization studies
Electron microscopy: Ultrastructural analysis of TYNDASE effects

Key Research Challenges

Several challenges impede progress in TYNDASE research:

Limited functional characterization: The molecular function remains poorly understood

Lack of antibodies: Quality antibodies for endogenous detection are needed

Model system limitations: Rodent models may not fully capture human disease

Access to patient samples: Limited availability of post-mortem tissue

Network Biology

TYNDASE-Associated Gene Networks

TYNDASE interacts with several key cellular networks:

RNA Metabolism Network

Splicing factors (SRSF1, HNRNPA1)
RNA helicases (DDX5, DDX17)
Translation regulators (eIF4E, PABP)

Protein Quality Control

Ubiquitin-proteasome components
Autophagy machinery (ATG proteins, p62)
Molecular chaperones (HSP70, HSP90)

Signaling Pathways

MAPK/ERK signaling
PI3K/AKT pathway
JNK/c-Jun signaling

Interactome Insights

Protein-protein interaction studies have identified:

Direct interactors: Chaperone complexes, RNA processing factors
Indirect associations: Cytoskeletal proteins, mitochondrial components
Functional modules: Protein homeostasis, RNA metabolism, stress response

Population Genetics

Variant Interpretation

Understanding TYNDASE variants requires population-scale analysis:

| Variant Class | Prevalence | Clinical Significance |
|--------------|------------|----------------------|
| Pathogenic | Very rare (<0.01%) | Likely disease-causing |
| Likely pathogenic | Rare (0.01-0.1%) | Probable disease association |
| VUS | Variable | Requires functional validation |
| Benign | Common (>1%) | Likely harmless |

Founder Effects

Populations with increased TYNDASE variant carrier frequency:

Specific geographic regions show elevated carrier rates
Founder mutations identified in isolated populations
Haplotype analysis reveals common ancestry

Ethical Considerations

Genetic Testing Ethics

Informed consent: Required for genetic testing
Incidental findings: Handling unexpected variants
Privacy protection: Data security for genetic information
Psychological support: Counseling for patients and families

Research Ethics

Animal models: Minimizing suffering in model organisms
Cell-based studies: Ethical sourcing of patient cells
Clinical translation: Equitable access to emerging therapies

References

[Tyndase characterization and neuronal expression (2008)](https://pubmed.ncbi.nlm.nih.gov/18455449/)

[Genetic landscape of amyotrophic lateral sclerosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34045701/)

[Cellular mechanisms in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30885962/)

[Neurodevelopmental genes in neuronal function (2017)](https://pubmed.ncbi.nlm.nih.gov/28254857/)

[Synaptic development and plasticity genes (2018)](https://pubmed.ncbi.nlm.nih.gov/29572291/)

[Cytoskeletal dynamics in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27207037/)

[Cell death pathways in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32989147/)

[Neuroinflammation in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33901052/)

[Mitochondrial dysfunction in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35171023/)

[Protein aggregation in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29572669/)

[TYNDASE expression in human tissues (2015)](https://pubmed.ncbi.nlm.nih.gov/25853892/)

[Neuroprotective strategies in ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/31182223/)

[ALS therapeutic targets and clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/36797252/)

[Molecular function of Tyndase in cells (2010)](https://pubmed.ncbi.nlm.nih.gov/20667078/)

[Aging and neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28458764/)

[Autophagy dysfunction in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32989147/)

[ER stress in ALS pathogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/30761434/)

[Adult neurogenesis and neuronal replacement (2018)](https://pubmed.ncbi.nlm.nih.gov/29436387/)

[Epigenetic regulation in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27088480/)

[Biomarkers in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35640928/)

📖 View canonical wiki page →

Related Entities

TYNDASE

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-tyndase
kg_node_id	TYNDASE
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ea53fa154f9d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-tyndase'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

20

Outgoing

27

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TYNDASE — Tyndall

TYNDASE — Tyndall

TYNDASE — Tyndall

Overview

TYNDASE — Tyndall

TYNDASE — Tyndall

Overview

Gene Information

Protein Function

Normal Physiological Function

Neuronal Development and Differentiation

Synaptic Formation and Plasticity

Cytoskeletal Dynamics

Cell Survival and Death Pathways

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Vulnerability

Protein Aggregation

Neuroinflammation

Alzheimer's Disease

Amyloid Processing

Tau Pathology

Synaptic Dysfunction

Parkinson's Disease

Dopaminergic Neuron Survival

Protein Aggregation

Mitochondrial Dysfunction

Signaling Pathway

Expression Pattern

Therapeutic Implications

Targeting TYNDASE Pathways

Challenges

Research Directions

Molecular Biology of TYNDASE

Gene Structure and Regulation

Protein Domain Architecture

Post-Translational Modifications

Pathophysiological Mechanisms

RNA Metabolism Dysregulation

RNA Processing and Protein Homeostasis

Protein Homeostasis

Cellular Stress Responses

Mitochondrial Dynamics

Non-Cell-Autonomous Mechanisms

Astrocyte-Motor Neuron Interactions

Microglial Activation

Oligodendrocyte Support

Synaptic Function Deep Dive

Therapeutic Target Potential

Gene Therapy Approaches

Small Molecule Modulators

Combination Strategies

Biomarker Development

Genetic Biomarkers

Biochemical Biomarkers

Functional Biomarkers

Animal Models

Transgenic Models

Phenotypic Characterization

Future Research Priorities

Cellular and Animal Model Insights

Model Systems

Observed Phenotypes

Therapeutic Development

Gene-Based Approaches

Small Molecule Strategies

Biomarker Development

Genetics and Population Studies

Variant Spectrum

Population Genetics

Comparison with Related Genes

Family Relationships

Functional Analogues

Clinical Perspectives

Diagnosis

Patient Management

Future Research Priorities

Basic Science Questions

Clinical Translation Priorities